Madrigal Pharmaceuticals (MDGL) EBT (2019 - 2025)
Historic EBT for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to -$111.1 million.
- Madrigal Pharmaceuticals' EBT fell 388.35% to -$111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$286.0 million, marking a year-over-year increase of 4485.68%. This contributed to the annual value of -$465.9 million for FY2024, which is 2469.34% down from last year.
- Per Madrigal Pharmaceuticals' latest filing, its EBT stood at -$111.1 million for Q3 2025, which was down 388.35% from -$42.2 million recorded in Q2 2025.
- Over the past 5 years, Madrigal Pharmaceuticals' EBT peaked at -$42.2 million during Q2 2025, and registered a low of -$152.0 million during Q2 2024.
- Over the past 5 years, Madrigal Pharmaceuticals' median EBT value was -$76.9 million (recorded in 2023), while the average stood at -$84.4 million.
- Per our database at Business Quant, Madrigal Pharmaceuticals' EBT plummeted by 9187.08% in 2024 and then surged by 7220.59% in 2025.
- Madrigal Pharmaceuticals' EBT (Quarter) stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then plummeted by 30.6% to -$112.2 million in 2023, then skyrocketed by 47.04% to -$59.4 million in 2024, then plummeted by 87.02% to -$111.1 million in 2025.
- Its EBT was -$111.1 million in Q3 2025, compared to -$42.2 million in Q2 2025 and -$73.2 million in Q1 2025.